Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28085982 | 0.98 | HDAC1 (0.39) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL27947608 | 0.98 | HDAC1 (0.39) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL27662317 | 0.98 | HDAC1 (0.39) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL27868897 | 0.98 | HDAC1 (0.39) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL6024664 | 0.94 | CA1 (0.38) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL1512279 | 0.86 | CA14 (0.43) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL27910088 | 0.84 | TDP1 (0.46) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL5287476 | 0.84 | HDAC6 (0.39) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL8310669 | 0.83 | CA14 (0.41) | CA14HDAC6CA1HDAC1HDAC2 | |
| SCHEMBL27866557 | 0.82 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105683196-A | Aryl ether based kinase inhibitors | 百时美施贵宝公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-104144932-A | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2014-11-12 | — | — | CN | disclosed |
| CN-103608332-A | Pyridine-2-amides useful as CB2 agonists | HOFFMANN LA ROCHE | 2014-02-26 | — | — | CN | disclosed |
| CN-102971286-A | New cathepsin S protease inhibitors for the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | MEDIVIR UK LTD | 2013-03-13 | — | — | CN | disclosed |
| CN-102177150-A | Dithiolane compounds, compositions containing them and their use in photoprotection of the skin | OREAL | 2011-09-07 | — | — | CN | disclosed |
| CN-102131775-A | Small molecule inhibitors of N-terminus activation of the androgen receptor | BRITISH COLUMBIA CANCER AGENCY | 2011-07-20 | — | — | CN | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| CN-101951770-A | Hcv protease inhibitors and uses thereof | AVILA THERAPEUTICS INC | 2011-01-19 | — | — | CN | disclosed |
| CN-100588653-C | Compound with proteasome inhibition function and its preparing method and application | UNIV BEIJING | 2010-02-10 | — | — | CN | disclosed |
| CN-101600691-A | Acyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-101085765-A | Compound with proteasome inhibition function and its preparing method and application | UNIV BEIJING (CN) | 2007-12-12 | — | — | CN | disclosed |
| EP-1799653-A2 | NOVEL HETEROCYCLES | Bayer Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006023843-A2 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | CA14 4501/4885HDAC6 1401/4885CA1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.